Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | P-CD19CD20-ALLO1 |
Synonyms | |
Therapy Description |
P-CD19CD20-ALLO1 are allogeneic T stem cell-rich T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20, which potentially induces antitumor activity against CD19 and CD20-expressing tumor cells (Blood (2024) 144 (Supplement 1): 4805). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
P-CD19CD20-ALLO1 | P-CD19CD20-ALLO-1|P-CD19CD20-ALLO 1 | CD19 Immune Cell Therapy 65 CD20 Immune Cell Therapy 13 | P-CD19CD20-ALLO1 are allogeneic T stem cell-rich T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20, which potentially induces antitumor activity against CD19 and CD20-expressing tumor cells (Blood (2024) 144 (Supplement 1): 4805). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |